8Monitoring systemic lupus erythematosus in standard clinical care
Introduction
Systemic lupus erythematosus (SLE) is always challenging for the clinician. Not only can it affect almost any organ system but it is often difficult to determine whether organ dysfunction is due to disease activity, organ damage, or both. Both SLE and its treatment can permanently damage organs. The quality of life in SLE is poor, leading to social and disability issues. This chapter addresses each domain of SLE: disease activity, organ damage, and quality of life, in terms of their monitoring in standard clinical care. The use of disease activity indices in the clinic and of a cumulative history summary to track complicated patients over time is discussed and summaries of monitoring guidelines for damage from the disease and for the toxicity of its treatments included.
Section snippets
Disease activity
SLE activity has three general patterns: ‘flare’ (or ‘relapsing remitting’), ‘chronic’ activity, or ‘long quiescence’ (or ‘remission’).
In the flare pattern, patients are usually well inbetween exacerbations.1 The exacerbations occur suddenly and unpredictably, sometimes overnight. Precipitants of flare are often not identified but can include ultraviolet light, the use of drugs or nutriceuticals that ‘activate’ the immune system (e.g. echinacea), infections, surgery, pregnancy, and sulfonamide
Monitoring disease activity
A stable SLE patient can be seen at quarterly intervals. An unstable SLE patient might require weekly follow-up. At each visit, an interval history is necessary. Because SLE can change over time, it is very helpful to have a summary sheet of past organ manifestations. An example of the Hopkins Lupus Cohort cumulative history form is shown in Figure 1. In a complicated patient, such a historical summary can avoid the need for large paper charts and for reviewing multiple notes in an electronic
Disease activity indices
To be used in standard clinical care, a disease activity index (DAI) must be short and easy to complete. Several such indices have been developed for use in the routine clinic setting. One, the Lupus Activity Index, is a visual analog scale for the physician's estimate of activity overall and for individual organs.11 A second practical DAI is the SLEDAI and its updated versions – the SELENA-SLEDAI12 and the SLEDAI-2K.13 Both types of DAI make it possible to summarize on one page the disease
Conclusion
Although few guidelines have been developed or tested for SLE, there is a general consensus on how to monitor SLE, how to monitor and prevent organ damage; and on the role of fatigue and fibromyalgia in the poor quality of life of the average patient with SLE.
References (45)
- et al.
Neonatal lupus: basic research and clinical perspectives
Rheumatic Diseases Clinics of North America
(2005) - et al.
Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
Lancet
(1996) - et al.
The bimodal mortality pattern of systemic lupus erythematosus
The American Journal of Medicine
(1976) - et al.
Timed urine collections are not needed to measure urine protein excretion in clinical practice
American Journal of Kidney Diseases
(2006) - et al.
Patterns of disease activity in systemic lupus erythematosus
Arthritis and Rheumatism
(1999) - et al.
Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus
Arthritis and Rheumatism
(2001) - et al.
A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus
Arthritis and Rheumatism
(2001) - et al.
Clinically active serologically quiescent systemic lupus erythematosus
The Journal of Rheumatology
(2003) - et al.
Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review
Acta Obstetricia et Gynecologica Scandinavica
(2006) - et al.
The impact of increased lupus activity on obstetric outcomes
Arthritis and Rheumatism
(2005)
The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials
Arthritis and Rheumatism
Simple method for monitoring 24-hour urinary urea nitrogen excretion
The Journal of Laboratory and Clinical Medicine
Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis
The Journal of Rheumatology
Validity and reliability of lupus activity measures in the routine clinic setting
The Journal of Rheumatology
Combined oral contraceptives in women with systemic lupus erythematosus
The New England Journal of Medicine
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE
The Journal of Rheumatology
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
The Quarterly Journal of Medicine
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity
Arthritis and Rheumatism
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College Rheumatology damage index for sytemic lupus erythematosus
Arthritis and Rheumatism
Damage in systemic lupus erythematosus and its association with corticosteroids
Arthritis and Rheumatism
Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines
Arthritis and Rheumatism
DHEA in elderly women and DHEA or testosterone in elderly men
The New England Journal of Medicine
Cited by (15)
Systemic lupus erythematosus: Safe and effective management in primary care
2010, Primary Care - Clinics in Office PracticeCitation Excerpt :For those patients with SLE whose joint or pericardial inflammation is associated with other manifestations that require corticosteroids, low to moderate doses of prednisone may preferable to NSAIDs pending the delayed onset of action of HCQ. The risks of chronic corticosteroid therapy for lupus have been well documented,26,27 but the benefits have not been quantified in recent controlled trials. Accordingly, recommendations about when to use corticosteroids and how much to use are somewhat a matter of personal opinion.
Correlation of Serum Neopterin level with Complement C3, C4 in assessment of Systemic Lupus Erythematosus Activity
2018, The Egyptian Journal of Hospital MedicineFamily physician and connective tissue Disorders
2013, Revue Medicale Suisse